



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95145

Hiroyuki NAKAHIRA, et al.

Appln. No.: 10/580,321

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Unknown

Filed: May 25, 2006

For: NOVEL CONDENSED IMIDAZOLE DERIVATIVE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. WO 2004/111051 A1, published December 23, 2004 was cited on International Search Report filed May 25, 2006.
2. WO 2004/50658 A1, published June 17, 2004 was cited on International Search Report filed May 25, 2006.
3. WO 2004/28524 A1, published April 8, 2004 was cited on International Search Report filed May 25, 2006.

HiroYuki NAKAHIRA, et al.
U.S. Appln. No.: 10/580,321
INFORMATION DISCLOSURE STATEMENT

4. WO 2003/104229 A1, published December 8, 2003 was cited on International Search Report filed May 25, 2006.
5. WO 2003/004496 A1, published January 16, 2003 was cited on International Search Report filed May 25, 2006.
6. J. Langner et al., "Cellular Peptidases in Immune Functions and Diseases 2", Advance in Experimental Medicine and Biology, Vol. 477.
7. L. Knudsen et al, "Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagons-like peptide-1(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor", European Journal of Pharmacology, Vol. 318, (1996), pp. 429-435.
8. T.J. Kieffer et al., "Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in *Vitor* and *Vivo* by Dipeptidyl Peptidase IV", Endocrinology, Vol. 136, (1995), pp. 3585-3596.
9. R.A. Pederson et al., "Improved Glucose Tolerance in Zucker Fatty Rats by Oral Admistration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide", Diabetes, Vol. 47, (1998), pp. 1253-1258.
10. WO 02/002560 A1, published January 10, 2002.
11. WO 02/068420 A1, published September 6, 2002.
12. WO 02/024965 A1, published March 27, 2003.
13. WO 02/024698 A1, published March 28, 2002.

One copy of each of the listed documents is submitted herewith.

Hiroiyuki NAKAHIRA, et al.
U.S. Appln. No.: 10/580,321
INFORMATION DISCLOSURE STATEMENT

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE


23373

CUSTOMER NUMBER



John T. Callahan
Registration No. 32,607

Date: August 4, 2006

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/580,321
				Confirmation Number	Unknown
				Filing Date	May 25, 2006
				First Named Inventor	Hiroyuki NAKAHIRA
				Part Unit	Unknown
				Examiner Name	Unknown
Sheet 1 of 1				Attorney Docket Number	Q95145

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	02/002560	A1	01/10/2002		
		WO	02/068420	A1	09/06/2002		
		WO	02/024965	A1	03/27/2003		
		WO	02/024698	A1	03/28/2002		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		J. Langner et al., "Cellular Peptidases in Immune Functions and Diseases 2", Advance in Experimental Medicine and Biology, Vol. 477.	
		L. Knudsen et al, "Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagons-like peptide-1(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor", European Journal of Pharmacology, Vol. 318, (1996), pp. 429-435.	
		T.J. Kieffer et al., "Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in <i>Vitor</i> and <i>Vivo</i> by Dipeptidyl Peptidase IV", Endocrinology, Vol. 136, (1995), pp. 3585-3596.	
		R.A. Pederson et al., "Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide", Diabetes, Vol. 47, (1998), pp. 1253-1258.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.